Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Licensing, PTSC, TPL/Moore

Licensing, PTSC, TPL/Moore

posted on Aug 28, 2009 07:48PM

Interestingly, Alliacense are contractually bound to use their best efforts in securing licenses. As PTSC have an undisputed 50% ownership of the MMP Portfolio, whatever is ongoing between Moore and TPL should have no impact as any licenses would be valid purely on PTSC's part ownership

It has been suggested that the above statement somehow implies that PTSC would attempt to license the MMP Portfolio outside of the Agreement. This is not correct. Alliacense could still continue to validly license the MMP Portfolio, on behalf of PTSC/TPL, as per the Agreement, regardless of the Moore/TPL spat, on the basis of PTSC's undisputed 50% rights.

I trust that this clarifies any uncertainties.

.

.

Be well

Share
New Message
Please login to post a reply